File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Bone and renal safety are improved in chronic hbv patients 1 year after switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF)

TitleBone and renal safety are improved in chronic hbv patients 1 year after switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF)
Authors
Issue Date2019
PublisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
Citation
International Digestive Disease Forum (IDDF) 2019, Hong Kong, 8–9 June 2019. In Gut, 2019, v. 68 n. Suppl. 1, p. A141-A142, abstract no. IDDF2019-ABS-0168 How to Cite?
AbstractBackground TAF has shown efficacy non-inferior to that of TDF at Week 96 with less bone and renal effects. Following implementation of a protocol amendment to extend double-blind (DB) treatment for an additional year, 50% of patients were able to continue on DB treatment while the remainder had already rolled-over to open-label (OL) TAF at Week 96. Here we compared the efficacy and safety from Week 96 to 144 in patients randomized to TDF in whom treatment was either continued or switched to TAF at Week 96.Methods In 2 identically-designed studies, 1298 HBeAg-negative and HBeAg-positive CHB patients (873 TAF, 425 TDF) were randomized and treated. In the TDF group, 211 remained on TDF (DB TDF) while 180 patients were switched to OL TAF (TDF→TAF) at Week 96. Safety assessments including changes in bone (hip and spine BMD) and renal (CrCl by Cockcroft-Gault [eGFRCG], serum creatinine) parameters, viral suppression, and biochemical responses were assessed in all patients from Week 96 to Week 144.Results Patient characteristics were similar for those who continued TDF and those switched to TAF. In the TDF→TAF group, improvements in eGFRCG were observed, while those remaining on DB TDF showed a continued decrease in eGFRCG at Week 144 (table 1). Similarly, significant improvements in hip and spine BMD were seen over 1 year in TDF→TAF patients while those remaining on TDF either had continued BMD declines or smaller increases (figure 1). High rates of virologic suppression (HBV DNA <29 IU/mL) were maintained in both groups (TDF→TAF 84% and DB TDF 88%; M=F), while a greater rate of ALT normalization (by 2018 AASLD criteria) was seen in TDF→TAF patients at 1 year following switch (45% vs 29%; M=F).View this table:Abstract IDDF2019-ABS-0168 Table 1 Efficacy and safety renal and bone results from week 96 to week 144Abstract IDDF2019-ABS-0168 Figure 1 Conclusions Virologic control was maintained and ALT normalization was increased following switch from TDF to TAF. However, compared to those remaining on TDF for an additional year, patients switched to TAF had improved bone and renal safety.
DescriptionClinical Hepatology - abstract no. IDDF2019-ABS-0168
Persistent Identifierhttp://hdl.handle.net/10722/280922
ISSN
2019 Impact Factor: 19.819
2015 SCImago Journal Rankings: 6.474

 

DC FieldValueLanguage
dc.contributor.authorChan, HLY-
dc.contributor.authorSeto, WKW-
dc.contributor.authorButi, M-
dc.contributor.authorIzumi, N-
dc.contributor.authorLim, YS-
dc.contributor.authorKao, J-
dc.contributor.authorStreinu-Cercel, A-
dc.contributor.authorNurmukhametova, E-
dc.contributor.authorMa, X-
dc.contributor.authorTabak, F-
dc.contributor.authorJablkowski, M-
dc.contributor.authorSuri, V-
dc.contributor.authorFlaherty, J-
dc.contributor.authorLau, A-
dc.contributor.authorGaggar, A-
dc.contributor.authorMo, S-
dc.contributor.authorChowdhury, A-
dc.contributor.authorFung, S-
dc.contributor.authorChuang, W-
dc.contributor.authorGane, E-
dc.date.accessioned2020-02-25T07:42:48Z-
dc.date.available2020-02-25T07:42:48Z-
dc.date.issued2019-
dc.identifier.citationInternational Digestive Disease Forum (IDDF) 2019, Hong Kong, 8–9 June 2019. In Gut, 2019, v. 68 n. Suppl. 1, p. A141-A142, abstract no. IDDF2019-ABS-0168-
dc.identifier.issn0017-5749-
dc.identifier.urihttp://hdl.handle.net/10722/280922-
dc.descriptionClinical Hepatology - abstract no. IDDF2019-ABS-0168-
dc.description.abstractBackground TAF has shown efficacy non-inferior to that of TDF at Week 96 with less bone and renal effects. Following implementation of a protocol amendment to extend double-blind (DB) treatment for an additional year, 50% of patients were able to continue on DB treatment while the remainder had already rolled-over to open-label (OL) TAF at Week 96. Here we compared the efficacy and safety from Week 96 to 144 in patients randomized to TDF in whom treatment was either continued or switched to TAF at Week 96.Methods In 2 identically-designed studies, 1298 HBeAg-negative and HBeAg-positive CHB patients (873 TAF, 425 TDF) were randomized and treated. In the TDF group, 211 remained on TDF (DB TDF) while 180 patients were switched to OL TAF (TDF→TAF) at Week 96. Safety assessments including changes in bone (hip and spine BMD) and renal (CrCl by Cockcroft-Gault [eGFRCG], serum creatinine) parameters, viral suppression, and biochemical responses were assessed in all patients from Week 96 to Week 144.Results Patient characteristics were similar for those who continued TDF and those switched to TAF. In the TDF→TAF group, improvements in eGFRCG were observed, while those remaining on DB TDF showed a continued decrease in eGFRCG at Week 144 (table 1). Similarly, significant improvements in hip and spine BMD were seen over 1 year in TDF→TAF patients while those remaining on TDF either had continued BMD declines or smaller increases (figure 1). High rates of virologic suppression (HBV DNA <29 IU/mL) were maintained in both groups (TDF→TAF 84% and DB TDF 88%; M=F), while a greater rate of ALT normalization (by 2018 AASLD criteria) was seen in TDF→TAF patients at 1 year following switch (45% vs 29%; M=F).View this table:Abstract IDDF2019-ABS-0168 Table 1 Efficacy and safety renal and bone results from week 96 to week 144Abstract IDDF2019-ABS-0168 Figure 1 Conclusions Virologic control was maintained and ALT normalization was increased following switch from TDF to TAF. However, compared to those remaining on TDF for an additional year, patients switched to TAF had improved bone and renal safety.-
dc.languageeng-
dc.publisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/-
dc.relation.ispartofGut-
dc.relation.ispartofInternational Digestive Disease Forum (IDDF) 2019-
dc.rightsGut. Copyright © BMJ Publishing Group.-
dc.titleBone and renal safety are improved in chronic hbv patients 1 year after switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF)-
dc.typeConference_Paper-
dc.identifier.emailSeto, WKW: wkseto@hku.hk-
dc.identifier.authoritySeto, WKW=rp01659-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1136/gutjnl-2019-IDDFAbstracts.277-
dc.identifier.hkuros309231-
dc.identifier.volume68-
dc.identifier.issueSuppl. 1-
dc.identifier.spageA141-
dc.identifier.epageA142-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats